MoonLake Immunotherapeutics Debt-to-Assets Ratio Growth & History (MLTX)

MoonLake Immunotherapeutics's debt-to-assets ratio was 0.18 for fiscal 2025.

View full MoonLake Immunotherapeutics company overview

MoonLake Immunotherapeutics annual debt-to-assets ratio history

MoonLake Immunotherapeutics annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-12-310.180.17+2912.87%
20242024-12-310.01−0.00−15.70%
20232023-12-310.010.00+90.98%
20222022-12-310.00−1.55−99.76%
20212021-12-311.55

MoonLake Immunotherapeutics debt-to-assets ratio trends

Between the periods ended 2021-12-31 and 2025-12-31, MoonLake Immunotherapeutics's debt-to-assets ratio decreased from 1.55 to 0.18, a change of −1.37. The latest reported quarter, Q2 2026, shows 0.18.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review MoonLake Immunotherapeutics source filings ↗

Community posts

It’s quiet here.

No posts about MLTX yet. Start the conversation.

Write the first post